NCT06369766 REtinal Markers In Neuroinflammatory Diseases ("REMIND")
| NCT ID | NCT06369766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-01-31 |
| Primary Completion | 2028-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study, including patients with Multiple Sclerosis, patients with other neuroinflammatory diseases and healthy controls, is to determine the predictive value of retinal markers in predicting disease progression. Participants complete a questionnaire and undergo various non-invasive retinal routine clinical examinations.
Eligibility Criteria
Inclusion Criteria: 1. All groups: * Age \>18 years old 2. Patients with Multiple Sclerosis: * Diagnosis of Multiple Sclerosis, according to the last revisions of the McDonald Criteria (2017) 3. Patients with other neuroinflammatory diseases: * Diagnosis of Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease or other neuroinflammatory disorders other than Multiple Sclerosis Exclusion Criteria: 1. All groups: * Inability to undergo Optical Coherence Tomography (OCT) and/or retinal vessel imaging (e.g. severe nystagmus that prevents eye fixation on both eyes) * Presence of any ocular pathology that may interfere with the validity of the OCT/retinal vessel analysis (cataracts, glaucoma, history of refractive defects \>6 D etc.). * Pregnancy and Lactation 2. Healthy Controls * History of other neurological conditions: participants with a history of other significant neurological conditions that might interfere with the assessment or interpretation
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.